Skip to main content

FDA Says ADHD Med Adderall Is in Short Supply

THURSDAY, Oct. 13, 2022 -- People with attention-deficit/hyperactivity disorder (ADHD) or narcolepsy may rely on the drug Adderall, but it is in short supply, the U.S. Food and Drug Administration announced Wednesday.

The Adderall and Adderall IR shortage is due to intermittent manufacturing delays at Teva, one of the companies that produces the medication.

While other companies continue to produce these amphetamine mixed salts, they don't make enough to meet U.S. demand.

Adderall is FDA-approved for ADHD and narcolepsy, a sleep disorder.

Until supply is restored, alternatives include the extended-release version of amphetamine mixed salts, the FDA said.

The FDA has posted information online on current manufacturers and available product strengths. It is monitoring the shortage and helping manufacturers get what they need to resolve it. The agency said it would continue to provide updates.

Patients should work with their doctors to determine their best treatment option, according to a news release from the FDA's Center for Drug Evaluation and Research.


  • Center for Drug Evaluation and Research, news release, Oct. 12, 2022

© 2023 HealthDay. All rights reserved.

Read this next

Target Recalls Over 200,000 Weighted Blankets After 2 Children Suffocated

TUESDAY, Dec. 27, 2022 – The U.S. Consumer Product Safety Commission and Target Corp. have issued a recall for more than 200,000 Pillowfort weighted blankets for children...

Youngest Kids in Class More Likely to Get Prescribed ADHD Meds

FRIDAY, Dec. 16, 2022 -- Kids who are the youngest in their grade may be overmedicated for attention deficit hyperactivity disorder (ADHD), according to a Norwegian researcher who...

What's Driving the Ongoing Adderall Shortage -- and What Parents Can Do

TUESDAY, Dec. 13, 2022 -- Shortages of the ADHD drug Adderall are expected to continue for months, forcing families to scramble for ways to deal with their children's attention...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.